Table 1.
Baseline demographics and clinical characteristics.
| eGFR <60 mL/min/1.73 m2 | eGFR ≥60 mL/min/1.73 m2 | |||
|---|---|---|---|---|
| Isa-Pd (n = 55) | Pd (n = 49) | Isa-Pd (n = 87) | Pd (n = 96) | |
| Median age, years (range) | 71 (39–83) | 67 (41–86) | 66 (36–82) | 64 (41–81) |
| Female, n (%) | 22 (40.0) | 26 (53.1) | 38 (43.7) | 54 (56.3) |
| Age categories, n (%) | ||||
| <65 years | 15 (27.3) | 18 (36.7) | 34 (39.1) | 49 (51.0) |
| 65–74 years | 21 (38.2) | 16 (32.7) | 42 (48.3) | 35 (36.5) |
| ≥75 years | 19 (34.5) | 15 (30.6) | 11 (12.6) | 12 (12.5) |
| Median time since diagnosis, years (range) | 4.4 (1.3–11.1) | 4.5 (1.2–15.8) | 4.9 (0.6–18.4) | 4.0 (0.5–20.5) |
| Type of myeloma at diagnosis, n (%) | ||||
| IgA | 16 (29.1) | 9 (18.4) | 16 (18.4) | 30 (31.3) |
| IgG | 30 (54.5) | 34 (69.4) | 63 (72.4) | 60 (62.5) |
| Light chain (κ+λ) | 7 (12.7) | 6 (12.2) | 7 (8.0) | 5 (5.2) |
| ISS stagea at diagnosis, n (%) | ||||
| I | 7 (12.7) | 9 (18.4) | 27 (31.0) | 29 (30.2) |
| II | 14 (25.5) | 15 (30.6) | 30 (34.5) | 30 (31.3) |
| III | 23 (41.8) | 19 (38.8) | 16 (18.4) | 24 (25.0) |
| ISS stagea at study entry, n (%) | ||||
| I | 14 (25.5) | 7 (14.3) | 45 (51.7) | 42 (43.8) |
| II | 16 (29.1) | 16 (32.7) | 32 (36.8) | 36 (37.5) |
| III | 25 (45.5) | 25 (51.0) | 7 (8.0) | 16 (16.7) |
| Median bone marrow plasma cells at study entry, % (range) | 32.0 (0–100) | 30.0 (1.0–93.0) | 23.6 (0–100) | 30.0 (0–90.0) |
| Cytogenetic risk at study entryb, n (%) | ||||
| High | 9 (16.4) | 11 (22.4) | 11 (12.6) | 22 (22.9) |
| Standard | 36 (65.5) | 29 (59.2) | 63 (72.4) | 47 (49.0) |
| Missing | 10 (18.2) | 9 (18.4) | 13 (14.9) | 27 (28.1) |
| Median prior lines of therapy (range) | 3 (2–11) | 3 (2–10) | 3 (2–11) | 3 (2–9) |
| Prior therapy, n (%) | ||||
| Alkylating agent | 49 (89.1) | 47 (95.9) | 80 (92.0) | 93 (96.9) |
| Proteasome inhibitor | 55 (100) | 49 (100) | 87 (100) | 96 (100) |
| Lenalidomide | 55 (100) | 49 (100) | 87 (100) | 96 (100) |
| Refractory status, n (%) | ||||
| IMiD refractory | 52 (94.5) | 44 (89.8) | 83 (95.4) | 92 (95.8) |
| Lenalidomide refractory | 51 (92.7) | 42 (85.7) | 81 (93.1) | 90 (93.8) |
| PI refractory | 41 (74.5) | 42 (85.7) | 70 (80.5) | 69 (71.9) |
| Lenalidomide and PI refractory | 39 (70.9) | 37 (75.5) | 65 (74.7) | 66 (68.8) |
| Lenalidomide last line | 35 (63.6) | 22 (44.9) | 48 (55.2) | 59 (61.5) |
eGFR estimated glomerular filtration rate, Ig immunoglobulin, Isa isatuximab, ISS International Staging System, IMiD immunomodulatory drug, Pd pomalidomide and dexamethasone, PI proteasome inhibitor.
aISS staging was derived based on the combination of serum β2-microglobulin and albumin.
bHigh risk was defined as del(17p), t(4;14), or t(14;16) by fluorescence in situ hybridization. Cytogenetics was performed by a central laboratory with a cut-off of 50% for del(17p), and 30% for t(4;14) and t(14;16).